Compare ALEMBIC with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs NATCO PHARMA - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC NATCO PHARMA ALEMBIC/
NATCO PHARMA
 
P/E (TTM) x 78.4 35.1 223.3% View Chart
P/BV x 6.8 5.0 135.4% View Chart
Dividend Yield % 0.2 0.7 22.3%  

Financials

 ALEMBIC   NATCO PHARMA
EQUITY SHARE DATA
    ALEMBIC
Mar-18
NATCO PHARMA
Mar-19
ALEMBIC/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs72849 8.5%   
Low Rs34557 6.1%   
Sales per share (Unadj.) Rs4.7573.8 0.8%  
Earnings per share (Unadj.) Rs6.1176.0 3.5%  
Cash flow per share (Unadj.) Rs6.2198.2 3.2%  
Dividends per share (Unadj.) Rs0.206.25 3.2%  
Dividend yield (eoy) %0.40.9 42.5%  
Book value per share (Unadj.) Rs40.7842.7 4.8%  
Shares outstanding (eoy) m267.0336.50 731.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x11.31.2 919.5%   
Avg P/E ratio x8.74.0 217.2%  
P/CF ratio (eoy) x8.53.5 239.0%  
Price / Book Value ratio x1.30.8 156.1%  
Dividend payout %3.33.6 92.3%   
Avg Mkt Cap Rs m14,13925,660 55.1%   
No. of employees `000NA5.0 0.0%   
Total wages/salary Rs m2073,559 5.8%   
Avg. sales/employee Rs ThNM4,225.3-  
Avg. wages/employee Rs ThNM718.0-  
Avg. net profit/employee Rs ThNM1,295.9-  
INCOME DATA
Net Sales Rs m1,25520,945 6.0%  
Other income Rs m3701,302 28.4%   
Total revenues Rs m1,62522,247 7.3%   
Gross profit Rs m1117,948 1.4%  
Depreciation Rs m38810 4.7%   
Interest Rs m2193 0.9%   
Profit before tax Rs m4428,247 5.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m241,823 1.3%   
Profit after tax Rs m1,6306,424 25.4%  
Gross profit margin %8.937.9 23.3%  
Effective tax rate %5.422.1 24.5%   
Net profit margin %129.830.7 423.4%  
BALANCE SHEET DATA
Current assets Rs m1,86723,472 8.0%   
Current liabilities Rs m5917,287 8.1%   
Net working cap to sales %101.677.3 131.5%  
Current ratio x3.23.2 98.0%  
Inventory Days Days9492 102.2%  
Debtors Days Days7488 83.4%  
Net fixed assets Rs m1,79118,648 9.6%   
Share capital Rs m534365 146.3%   
"Free" reserves Rs m10,32434,525 29.9%   
Net worth Rs m10,85830,760 35.3%   
Long term debt Rs m410-   
Total assets Rs m11,59143,031 26.9%  
Interest coverage x260.943.7 596.6%   
Debt to equity ratio x00-  
Sales to assets ratio x0.10.5 22.2%   
Return on assets %14.115.4 91.5%  
Return on equity %15.020.9 71.9%  
Return on capital %15.227.4 55.4%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1911,536 0.2%   
Fx outflow Rs m2642,939 9.0%   
Net fx Rs m-2448,597 -2.8%   
CASH FLOW
From Operations Rs m2366,688 3.5%  
From Investments Rs m-224-6,122 3.7%  
From Financial Activity Rs m-27-509 5.2%  
Net Cashflow Rs m-1566 -22.4%  

Share Holding

Indian Promoters % 64.0 52.0 123.0%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 0.2 7.8 2.6%  
FIIs % 9.7 16.6 58.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 26.0 100.4%  
Shareholders   54,701 25,395 215.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   FULFORD INDIA  VENUS REMEDIES  CIPLA  WOCKHARDT  AUROBINDO PHARMA  

Compare ALEMBIC With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Snap 4-Day Winning Streak; JSW Steel and Hindalco Among Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


May 11, 2021 03:36 PM

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE ALEMBIC WITH

MARKET STATS